Response Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Point-of-care diagnostics developer raises $5 mil. via private placement of 5.9 mil. special warrants at $0.85 each. Funds will be used to scale up manufacturing of the RAMP reader and three cardiac marker assays, as well as for development of additional assays like prostate specific antigen. Participating in the financing is a syndicate of underwriters led by Yorkton Securities, Inc., including Haywood Securities and Acumen Capital Partners